BioWorld

Oct. 6, 2010

View Archived Issues

Cyclacel Seeks to Raise $22M for Phase III-Ready AML Drug

Read More

Biotechs Can Go Solo in Asian Markets, but Not Easy

Read More

Other News To Note

Read More

Stock Movers

Read More

Clinic Roundup

Read More

HGS, Novartis Bail on Zalbin After Thumbs Down from FDA

Upon receipt of a complete response letter from the FDA, Human Genome Sciences Inc. and Novartis AG have decided not to pursue Zalbin (albinterferon alfa-2b) in hepatitis C. (BioWorld Today) Read More

Panel: Correctly Managing IP Essential to Biotech Success

Read More